Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 3, 2013, Pages 445-449

  Lemieux, Emilie ^a   Hulin, Cyrille ^b   Caillot, Denis ^c   Tardy, Stéphanie ^b   Dorvaux, Véronique ^d   Michel, Jessica ^b   Gastinne, Thomas ^e   Rossi, Cédric ^c   Legouge, Caroline ^c   Touzeau, Cyrille ^e   Planche, Lucie ^e   Loirat, Marion ^e   Lafon, Ingrid ^c   Moreau, Philippe ^e  

^a Respiratory Medicine   (Canada)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d University Hospital   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Autologous stem cell transplantation; Multiple myeloma; Salvage therapy

Indexed keywords

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONSOLIDATION CHEMOTHERAPY; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONSOLIDATION CHEMOTHERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84873725774     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.11.013     Document Type: Article

References (31)

1. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996, 3335:91-97.
2. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
3. Moreau P., Avet-Loiseau H., Harousseau J.L., Attal M. Current trends in autologous stem cell transplantation for myeloma in the era of novel therapies. J Clin Oncol 2011, 29:1898-1906.
4. Richardson P.G., Sonneveld P., Schuster M., et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007, 110:3557-3560.
5. Weber D.M., Chen C., Niesvizky R., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007, 357:2133-2142.
6. Dimopoulos M., Spencer A., Attal M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357:2123-2132.
7. Garderet L., Iacobelli S., Moreau P., et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 randomized phase III trial from the chronic leukemia working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2012, 30:2475-2482.
8. Gertz M.A. Stem cell transplant: an effective salvage therapy for multiple myeloma. Leuk Lymph 2011, 52:1413-1414.
9. Olin R.L., Vogl D.T., Porter D.L., et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant 2009, 43:417-422.
10. Shah N., Ahmed F., Bashir Q., et al. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer 2012, 118:3549-3555.
11. Elice F., Raimondi R., Tosetto A., et al. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Am J Hematol 2006, 81:426-431.
12. Qazilbash M.H., Saliba R., De Lima M., et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006, 106:1084-1089.
13. Chow AW, Lee CH, Hiwase DK, et al. Relapsed multiple myloma: who benefits from salvage autografts? Blood (ASH Annual Meeting Abstracts) 2011;118:abstr 3059.
14. Saad AA, Vesole DH, Le-Rademacher J, et al. Second autologous transplants for multiple myeloma relapse after a prior autologous transplant-a report from the Center for International Blood and Marrow Transplant Research. Blood (ASH Annual Meeting Abstracts) 2011;118:abstr 504.
15. Alvares C.L., Davies F.E., Horton C., et al. The role of second autografts in the management of myeloma at first relapse. Haematologica 2006, 91:141-142.
16. Jimenez-Zepeda V.H., Mikhael J., Winter A., et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant 2012, 18:773-779.
17. Burzynski J.A., Toro J.J., Patel R.C., et al. Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymph 2009, 50:1442-1447.
18. Freytes CO, Vesole DH, Zhong X, et al. Second transplants in relapsed multiple myeloma: autologous versus non-myeloablative/reduced intensity allogenic transplantation. Blood (ASH Annual Meeting Abstracts) 2011;118:abstr 824.
19. Fenk R., Liese V., Neubauer F., et al. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leuk Lymph 2011, 52:1455-1462.
20. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
21. Jakubowiak A. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives. Semin Hematol 2012, 49(suppl 1):S16-S32.
22. Bird J.M., Owen R.G., D'Sa S., et al. Guidelines for the diagnosis and management of multiple myeloma. Br J Haematol 2011, 154:32-75.
23. Offidani M., Corvatta L., Morabito F., et al. How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions. Expert Opin Invest Drugs 2011, 20:779-793.
24. Lonial S., Mitsiades C.S., Richardson P.G. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 2011, 17:1264-1277.
25. Shah N., Lonial S. Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel-agents and high-dose chemotherapy and autologous stem-cell transplantation. Hematol Am Soc Hematol Educ Progr 2010, 1:310-313.
26. Mohty B., El-Cheikh J., Yakoub-Agha I., et al. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and retreatment approaches in the era of novel agents. Leukemia 2012, 26:73-85.
27. Lokhorst H., Einsele H., Vesole D., et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 2010, 28:4521-4530.
28. Ludwig H., Durie B.G., McCarthy P., et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood 2012, 119:3003-3015.
29. Attal M., Lauwers-Cances V., Marit G., et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012, 366:1782-1791.
30. McCarthy P.L., Owzar K., Hofmeister C.C., et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012, 366:1770-1781.
31. Giralt S., Stadtmauer E.A., Harousseau J.L., et al. International Myeloma Working Group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009, 23:1904-1912.